Henry Potozky

Bio: Henry Potozky is an academic researcher. The author has contributed to research in topics: Sarcoma & Ewing's tumor. The author has an hindex of 1, co-authored 1 publications receiving 11 citations.

Ewing's Tumor Simulating Sarcoma of Soft-Tissue Origin: A Clinical, Pathological and Radiotherapeutic Study of Four Cases

Abstract: The clinical, pathological and therapeutic aspects of Ewing's tumor, or endothelial myeloma of bone, have undergone progressive classification in the past decade. Its histogenesis and cytogenesis still remain somewhat controversial, although the majority of observers now reject an endothelial origin and tend to view it as arising from undifferentiated mesenchyme (1). From a clinical standpoint, the osteomyelitic syndrome which occasionally ushers in this neoplasm is well known. This onset is particularly common in children, dependent probably not on any intrinsic differences in the neoplasm in the different age groups but rather on varying capacities of the host. In adults the symptomatology is classically that of malignant bone tumors in general, with pain and disability as the outstanding complaints. Swelling or a palpable mass may also occur, but this again is more common in children (2). Soft-tissue masses, as distinguished from osseous swelling, occur late in the course of the disease and are usually associated with advanced bone pathology and frank cortical destruction. The soft-tissue mass may become very large in some cases and temporarily dominate the clinical picture, but only rarely does the primary origin of the neoplasm remain undiscovered.

A note from history: landmarks in history of cancer, part 5.

Abstract: In the 3 decades from 1910 to 1940, more progress took place in cancer research and the diagnosis and treatment of cancers than during the prior centuries combined. The discovery of several carcinogens, precancerous conditions, and hereditary cancers adduced new thoughts about the genesis of cancers. Even though diagnostic radiology and radiation therapy became apposite specialties, surgery retained its primacy in the treatment of cancer patients. The delineation of new and distinct neoplastic entities, several precancerous lesions, and noninvasive carcinomas as well as the introduction of histopathologic grading of cancers promulgated cogent changes in therapy. Yet, with all the advances in the diagnosis and treatment of cancers, very little betterment could be demonstrated in the overall survival of patients, and by the end of the 1930s, cancer became the second most common cause of death in the United States.

Die Ewingtumoren oder Omoblastome des Knochens

Abstract: Rundzellensarkome des Knochens sind seit der Mitte des vorigen Jahrhunderts bekannt Virchow (414), Lucke (252) und Billroth (18) haben sie als Erste beschrieben

Tumoren und tumorförmige Veränderungen des Weichgewebes

Abstract: Zu den Weichgewebstumoren gehoren nach der WHO-Definition alle mesenchymalen Tumoren, die zwischen Skelettsystem und Haut gelegen sind, mit Ausnahme der Tumoren des lymphatischen bzw. retikuloendothelialen Systems und der des Stutzgewebes spezieller Organe, z.B. der Viszera. Wegen der ahnlichen klinischen und histologisch differentialdiagnostischen Problematik werden die Tumoren des neuroektodermalen Gewebes des peripheren und autonomen Nervensystems mit eingeschlossen (WHO/Enzinger 1969). Dabei gibt es weder a) nach „oben“zur Haut, noch b) in der „Tiefe“zum Skelett scharfe Grenzen, wie z.B. a) bei Tumoren der glatten Muskulatur und bei fibrosen Histiozytomen der Dermis oder b) bei aggressiven Fibromatosen des Periost und synovialen Sarkomen der Gelenkkapsel. Der Begriff Weichgewebs-„Tu-mor“wird weit gefast: Oft ist die Frage, ob es sich um eine Neoplasie oder um eine tumorformige reaktive Zeilproliferation handelt, ungeklart (WHO/Enzinger 1969). Mit dem Ausdruck „maligne“oder Sarkom werden alle Weichgewebstumoren belegt, die die Fahigkeit zur Metastasierung besitzen, wenn auch oft mit extremen Unterschieden in bezug auf 1. Metastasenhaufigkeit und 2. Dauer des metastasenfreien Intervalls (WHO/Enzinger 1969; Meister 1981).